List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 80 studies with search of: platinum resistant | Interventional Studies | ovarian cancer
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: decitabine
2 Completed A Phase II Study of Weekly Docetaxel and Topotecan in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Docetaxel;   Drug: Topotecan
3 Active, not recruiting Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Biological: Intraperitoneal tgDCC-E1A;   Drug: Paclitaxel
4 Active, not recruiting MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: capecitabine
5 Recruiting Platinum Resistant Ovarian Cancer Evaluation of Doxil and EC145 Combination Therapy
Condition: Ovarian Cancer
Interventions: Drug: EC145;   Drug: pegylated liposomal doxorubicin (PLD);   Drug: EC20
6 Recruiting Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma
Condition: Ovarian Cancer
Interventions: Drug: Hycamptin;   Drug: Gemcitabine
7 Recruiting A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: BSI-201
8 Active, not recruiting Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer
Condition: Epithelial Ovarian Cancer
Intervention: Drug: Voreloxin Injection
9 Recruiting An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab);   Drug: 0.9% Saline
10 Recruiting Phase II Study of Weekly Topotecan With Bevacizumab in Platinum Resistant Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Intervention: Drug: bevacizumab and topotecan
11 Active, not recruiting Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: dexamethasone;   Drug: gemcitabine hydrochloride;   Drug: paclitaxel
12 Recruiting Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Biological: Sorafenib;   Drug: Topotecan
13 Terminated A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Peritoneal Neoplasms
Intervention: Drug: Volociximab
14 Recruiting Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-type
Condition: Epithelial Ovarian Cancer
Interventions: Drug: Pegylated liposomal doxorubicin;   Drug: Panitumumab
15 Active, not recruiting A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: CP-4055
16 Active, not recruiting Gleevec Study for Patients With Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: Imatinib Mesylate
17 Completed Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-Resistant Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: NOV-002
18 Recruiting A Study of Liposomal Doxorubicin With or Without IMC-3G3 in Platinum-refractory or Resistant Advanced Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Biological: IMC-3G3;   Drug: liposomal doxorubicin
19 Recruiting Pharmacokinetic Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)
Condition: Ovarian Cancer
Intervention: Drug: Doxil and Avastin
20 Not yet recruiting Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: Sorafenib

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services